Androgen Antagonists - Adverse effects
Research News and Information

Sunday, November 22, 2009

Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.

14 Sep 2009 PURPOSE: The profound hypogonadism due to androgen deprivation therapy for prostate cancer results in complications such as sexual dysfunction, poor quality of life, vasomotor symptoms and altered cognition. Since estrogen is associated with ... Read more...

Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.

14 Sep 2009 PURPOSE: Androgen deprivation therapy for prostate cancer is associated with osteoporosis and increased fracture risk. Previous studies of zoledronic acid demonstrated bone loss prevention in patients initiating androgen deprivation therapy. There ... Read more...

Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

9 Aug 2009 BACKGROUND: Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against ... Read more...

Latest indexed articles for 'Androgen Antagonists - Adverse effects'

These are the very latest articles for this heading:

• Degarelix (firmagon) for prostate cancer. 17 Oct 2009
• Editorial comment. 14 Sep 2009
• Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. 14 Sep 2009
• Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. 14 Sep 2009
• Denosumab in men receiving androgen-deprivation therapy for prostate cancer. 9 Aug 2009
• Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. 30 Jul 2009
• Synchronous bilateral breast cancer in a male patient following hormone therapy for prostate cancer. 9 Jul 2009
• Decreasing sex difference in birth weight. 29 Jun 2009
• Duration of androgen suppression in the treatment of prostate cancer. 9 Jun 2009
• New trial data do not end the PSA screening debate. 7 Jun 2009
• Impact of androgen deprivation therapy on cardiovascular disease and diabetes. 6 Jun 2009
• "Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer. 6 Jun 2009
• Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure. 31 May 2009
• [Trazodone: a new selective approach to the treatment of hot flashes induced by androgen deprivation in prostate carcinoma?] 30 May 2009
• Prostate cancer: issues in psychosomatic medicine. 30 May 2009
• Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. 30 May 2009
• Treatment of prostate cancer in unfit senior adult patients. 29 May 2009
• Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. 7 May 2009
• Skeletal sequelae of cancer and cancer treatment. 30 Apr 2009
• [Oncology forum in urology] 29 Apr 2009

See a longer list of these articles.

Technical information about 'Androgen Antagonists'

Definition: Compounds which inhibit or antagonize the biosynthesis or actions of androgens.

Registry Number: 0

Descriptor UI: D000726

Alternative terms: Androgen Antagonists; Antagonists, Androgen; Antiandrogens;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D06.347.065; D27.505.696.399.450.065;

History Note: 78

Technical Notes: DF: ANDROGEN ANTAG